Contact us

Our Facilities

Seda boasts world-class GMP manufacturing and testing facilities designed to advance your asset from development to clinical success.

 

Facilities and equipment

Located adjacent to our pharmaceutical development laboratories, our 50,000 sqft state-of-the-art GMP manufacturing and testing facility is perfectly placed to offer Seda clients a seamless transition from development through to clinic. Equally, we are able to transfer established products directly into the GMP facility.

Purpose built with its own dedicated team of experts and pharmaceutical quality system, the CMS facility has been optimally designed with quality control laboratories, production rooms including high potency, clean rooms, containment systems and office space, to assure compliance and maximum efficiency.

The Quality Control laboratory is equipped with the latest analytical equipment and data integrity systems to assure the provision robust and reproducible release and stability data.

The GMP manufacturing facility has been designed as a multi-product facility with 5 Grade D cleanrooms. Containment is achieved via a single pass (no recirculation) HEPA filtered air flow which maintains a pressure cascade into each room. Processing rooms are equipped with secondary air-locks to provide a barrier to common areas. Manufacture of high potent materials is achieved via both fixed and flexible secondary containment within each room.

Available manufacturing equipment includes:

  • Blenders
  • Roller Compactors
  • Mills
  • Capsule fillers (powders, liquids and semi-solids)
  • Tablet presses
  • Spray Dryer
  • Tablet coater
  • All associated in-process testing equipment

The facility is ‘solvent rated’ to enable spray drying from volatile/flammable solvent systems.


Virtual Tour

Ask our team a question

Paul W Stott

BPharm (Hons) PhD

Chief Executive Officer

Paul W Stott

BPharm (Hons) PhD

Chief Executive Officer

View Bio Ask me a question

Paul is an established pharma executive with extensive global experience. Prior to joining Seda he was Vice President, Global Product Development at AstraZeneca, leading a group of over 350 scientists and engineers in the development of all products, manufacturing processes and analytical methods for the AstraZeneca small molecule portfolio.

AstraZeneca Global Product Development has centres in the UK, Sweden, US and China and a network of partnerships with colleagues all over the world and under Paul’s stewardship registered 10 global products.

At AstraZeneca Paul was accountable for the Drug Product CMC component of all Due Diligence assessments and was CMC lead on several multibillion dollar acquisitions. In addition, Paul is a visiting Professor of Pharmaceutics at the University of Manchester, UK and founder of the North West Centre for Drug Delivery (NoWCADD) at the University.

He is a proven senior manager and strategic leader in Pharmaceutical Development with experience across geographical boundaries. Passionate about the development of individual and group capabilities and the application of innovation and scientific rigour to bring new medicinal products to market.

He is recognised within the Industry and with Regulatory Agencies as a driving force in the establishment and realisation of best practice in CMC Quality by Design.

‪Paul Stott‬ – ‪Google Scholar‬

Ask me a question

    Expect a reply typically within 48 hours.

    Marcel de Matas

    BSc (Hons) PhD FRSC CChem

    Chief Technology Officer & Co-Founder

    Marcel de Matas

    BSc (Hons) PhD FRSC CChem

    Chief Technology Officer & Co-Founder

    View Bio Ask me a question

    Marcel has a track record in a range of management and senior scientific positions in industry and academia. Most recently he was a Principal Scientist in Product Design and Innovation at AstraZeneca, where he was responsible for introducing the latest science, new technologies (advanced drug delivery and manufacturing) and product design thinking into the Product Development group.

    Marcel has led technical activities, provided project leadership and has managed product development teams responsible for the delivery of drug projects from initial concept design through late stage development, regulatory submission and launch (including advanced drug delivery systems). He has led teams at the drug discovery-development interface, assessing the level of chemistry manufacturing and controls (CMC) technical risk and defining product design strategies in early development. Project experience has covered projects across a range of disease and therapy areas with substantial experience in the oncology field.

    ‪Marcel de Matas‬ – ‪Google Scholar‬

    Ask me a question

      Expect a reply typically within 48 hours.

      Vijay Masaun

      BSc (Hons)

      Director, Quality Assurance

      Vijay Masaun

      BSc (Hons)

      Director, Quality Assurance

      View Bio Ask me a question

      Vijay is an experienced Quality Professional with a distinguished career marked by several senior quality roles within various pharmaceutical organisations primarily in the CDMO/CMO space.

      His comprehensive understanding of the pharmaceutical landscape, coupled with his strategic thinking, has enabled him to navigate the complexities of the evolving industry standards.

      Vijay has a proven track record spanning over 9 years in the pharmaceutical industry as well as training to be a Qualified Person (QP), which will bring valuable experience to the Seda GMP team and ensuring a commitment to upholding regulatory standards.

      Ask me a question

        Expect a reply typically within 48 hours.